1
|
van der Kolk MR, Janssen MACH, Rutjes FPJT, Blanco‐Ania D. Cyclobutanes in Small-Molecule Drug Candidates. ChemMedChem 2022; 17:e202200020. [PMID: 35263505 PMCID: PMC9314592 DOI: 10.1002/cmdc.202200020] [Citation(s) in RCA: 44] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 03/05/2022] [Indexed: 11/13/2022]
Abstract
Cyclobutanes are increasingly used in medicinal chemistry in the search for relevant biological properties. Important characteristics of the cyclobutane ring include its unique puckered structure, longer C-C bond lengths, increased C-C π-character and relative chemical inertness for a highly strained carbocycle. This review will focus on contributions of cyclobutane rings in drug candidates to arrive at favorable properties. Cyclobutanes have been employed for improving multiple factors such as preventing cis/trans-isomerization by replacing alkenes, replacing larger cyclic systems, increasing metabolic stability, directing key pharmacophore groups, inducing conformational restriction, reducing planarity, as aryl isostere and filling hydrophobic pockets.
Collapse
Affiliation(s)
- Marnix R. van der Kolk
- Institute for Molecules and MaterialsRadboud UniversityHeyendaalseweg 1356526 AJNijmegenThe Netherlands
| | - Mathilde A. C. H. Janssen
- Institute for Molecules and MaterialsRadboud UniversityHeyendaalseweg 1356526 AJNijmegenThe Netherlands
| | - Floris P. J. T. Rutjes
- Institute for Molecules and MaterialsRadboud UniversityHeyendaalseweg 1356526 AJNijmegenThe Netherlands
| | - Daniel Blanco‐Ania
- Institute for Molecules and MaterialsRadboud UniversityHeyendaalseweg 1356526 AJNijmegenThe Netherlands
| |
Collapse
|
2
|
Shinde AK, Badange RK, Reballi V, Achanta PK, Bojja K, Manchineella S, Rao Muddana N, Subramanian R, Choudary Palacharla R, Benade V, Jayarajan P, Thentu JB, Lingavarapu BB, Yarra S, Kagita N, Rao Doguparthi M, Mohammed AR, Nirogi R. 1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H 3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition. ChemMedChem 2021; 17:e202100583. [PMID: 34761873 DOI: 10.1002/cmdc.202100583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 11/06/2021] [Indexed: 11/10/2022]
Abstract
A series of chemical optimizations, which was guided by in vitro affinity at histamine H3 receptor (H3 R), modulation of lipophilicity, ADME properties and preclinical efficacy resulted in the identification of 1-[2-(1-cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one (45 e) as a potent and selective (Ki =4.0 nM) H3 R inverse agonist. Dipsogenia induced by (R)-α-methylhistamine was dose dependently antagonized by 45 e, confirming its functional antagonism at H3 R. It is devoid of hERG and phospholipidosis issues. Compound 45 e has adequate oral exposures and favorable half-life in both rats and dogs. It has demonstrated high receptor occupancy (ED80 =0.22 mg/kg) and robust efficacy in object recognition task and, dose dependently increased acetylcholine levels in brain. The sub-therapeutic doses of 45 e in combination with donepezil significantly increased acetylcholine levels. The potent affinity, selectivity, in vivo efficacy and drug like properties together with safety, warrant for further development of this molecule for potential treatment of cognitive disorders associated with Alzheimer's disease.
Collapse
Affiliation(s)
- Anil Karbhari Shinde
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Rajesh Kumar Badange
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Veena Reballi
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Pramod Kumar Achanta
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Kumar Bojja
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Sravanthi Manchineella
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Nageswara Rao Muddana
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Ramkumar Subramanian
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Raghava Choudary Palacharla
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Vijay Benade
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Pradeep Jayarajan
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Jagadeesh Babu Thentu
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Bujji Babu Lingavarapu
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Sivasekhar Yarra
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Narendra Kagita
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Mallikarjuna Rao Doguparthi
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Abdul Rasheed Mohammed
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| | - Ramakrishna Nirogi
- Drug Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500 034, India
| |
Collapse
|
3
|
Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, Bogaraju N, Middekadi VR, Subramanian R, Palacharla RC, Benade V, Muddana N, Abraham R, Medapati RB, Thentu JB, Mekala VR, Petlu S, Lingavarapu BB, Yarra S, Kagita N, Goyal VK, Pandey SK, Jasti V. Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT 4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease. J Med Chem 2021; 64:10641-10665. [PMID: 34251799 DOI: 10.1021/acs.jmedchem.1c00703] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer's disease. Starting from a reported 5-HT4R antagonist, a systematic structure-activity relationship was conducted, which led to the discovery of potent and selective 5-HT4R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, 12l). It showed balanced physicochemical-pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development.
Collapse
Affiliation(s)
- Ramakrishna Nirogi
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Abdul Rasheed Mohammed
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Anil Karbhari Shinde
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | | | | | - Srinivasa Rao Ravella
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Narsimha Bogaraju
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Vanaja Reddy Middekadi
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Ramkumar Subramanian
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | | | - Vijay Benade
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Nageswararao Muddana
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Renny Abraham
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Rajesh Babu Medapati
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Jagadeesh Babu Thentu
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Venkat Reddy Mekala
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Surendra Petlu
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Bujji Babu Lingavarapu
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Sivasekhar Yarra
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Narendra Kagita
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Vinod Kumar Goyal
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Santosh Kumar Pandey
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Venkat Jasti
- Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| |
Collapse
|
4
|
Nirogi R, Shinde A, Mohammed AR, Badange RK, Reballi V, Bandyala TR, Saraf SK, Bojja K, Manchineella S, Achanta PK, Kandukuri KK, Subramanian R, Benade V, Palacharla RC, Jayarajan P, Pandey S, Jasti V. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H 3 Receptor Inverse Agonist with Robust Wake-Promoting Activity. J Med Chem 2019; 62:1203-1217. [PMID: 30629436 DOI: 10.1021/acs.jmedchem.8b01280] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.
Collapse
Affiliation(s)
- Ramakrishna Nirogi
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Anil Shinde
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Abdul Rasheed Mohammed
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Rajesh Kumar Badange
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Veena Reballi
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Thrinath Reddy Bandyala
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Sangram Keshari Saraf
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Kumar Bojja
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Sravanthi Manchineella
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Pramod Kumar Achanta
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Kiran Kumar Kandukuri
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Ramkumar Subramanian
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Vijay Benade
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Raghava Choudary Palacharla
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Pradeep Jayarajan
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Santoshkumar Pandey
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Venkat Jasti
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| |
Collapse
|
5
|
Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Middekadi VR, Bogaraju N, Ravella SR, Singh P, Birangal SR, Subramanian R, Palacharla RC, Benade V, Muddana N, Jayarajan P. Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT 4 Receptor Partial Agonists. J Med Chem 2018; 61:4993-5008. [PMID: 29763304 DOI: 10.1021/acs.jmedchem.8b00457] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that has a higher prevalence and incidence in people older than 60 years. The need for improved AD therapies is unmet as the current therapies are symptomatic with modest efficacy. Partial agonists of the 5-HT4 receptor (5-HT4R) offer both symptomatic and disease-modifying treatments as they shift amyloid-precursor-protein (APP) processing from the amyloidogenic pathway to the nonamyloidogenic pathway by activating the α-secretase enzyme. In addition, they also offer symptomatic treatment by increasing levels of the neurotransmitter acetylcholine in the brain. Because of this fascinating dual mechanism of action, several chemical scaffolds having 5-HT4R pharmacophores were designed and evaluated. Most of the synthesized compounds showed potent in vitro affinities and in vivo efficacies. Upon analysis of focused structure-activity relationships, compound 4o was identified as a potent 5-HT4R partial agonist with favorable ADME properties and good in vivo efficacy. GR-125487, a selective 5-HT4R antagonist, attenuated the activity of compound 4o in the novel-object-recognition-test cognition model.
Collapse
Affiliation(s)
- Ramakrishna Nirogi
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Abdul Rasheed Mohammed
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Anil K Shinde
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Shankar Reddy Gagginapally
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Durga Malleshwari Kancharla
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Vanaja Reddy Middekadi
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Narsimha Bogaraju
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Srinivasa Rao Ravella
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Pooja Singh
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Sumit Raosaheb Birangal
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Ramkumar Subramanian
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Raghava Choudary Palacharla
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Vijay Benade
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Nageswararao Muddana
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| | - Pradeep Jayarajan
- Discovery Research , Suven Life Sciences Limited , Serene Chambers, Road-5, Avenue-7, Banjara Hills , Hyderabad 500 034 , India
| |
Collapse
|